These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 12910517)
1. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Rieger-Christ KM; Mourtzinos A; Lee PJ; Zagha RM; Cain J; Silverman M; Libertino JA; Summerhayes IC Cancer; 2003 Aug; 98(4):737-44. PubMed ID: 12910517 [TBL] [Abstract][Full Text] [Related]
2. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. van Rhijn BW; Lurkin I; Radvanyi F; Kirkels WJ; van der Kwast TH; Zwarthoff EC Cancer Res; 2001 Feb; 61(4):1265-8. PubMed ID: 11245416 [TBL] [Abstract][Full Text] [Related]
3. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. van Rhijn BW; Lurkin I; Chopin DK; Kirkels WJ; Thiery JP; van der Kwast TH; Radvanyi F; Zwarthoff EC Clin Cancer Res; 2003 Jan; 9(1):257-63. PubMed ID: 12538478 [TBL] [Abstract][Full Text] [Related]
4. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143 [TBL] [Abstract][Full Text] [Related]
5. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. van Oers JM; Lurkin I; van Exsel AJ; Nijsen Y; van Rhijn BW; van der Aa MN; Zwarthoff EC Clin Cancer Res; 2005 Nov; 11(21):7743-8. PubMed ID: 16278395 [TBL] [Abstract][Full Text] [Related]
6. Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay. Zuiverloon TC; Tjin SS; Busstra M; Bangma CH; Boevé ER; Zwarthoff EC J Urol; 2011 Aug; 186(2):707-12. PubMed ID: 21683397 [TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005 [TBL] [Abstract][Full Text] [Related]
8. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860 [TBL] [Abstract][Full Text] [Related]
9. Frequent FGFR3 mutations in urothelial papilloma. van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885 [TBL] [Abstract][Full Text] [Related]
10. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391 [TBL] [Abstract][Full Text] [Related]
11. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601 [TBL] [Abstract][Full Text] [Related]
12. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine. Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367 [TBL] [Abstract][Full Text] [Related]
13. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Amorós A; Tardón A; Carrato A; Serra C; Malats N; Real FX J Clin Oncol; 2006 Aug; 24(22):3664-71. PubMed ID: 16877735 [TBL] [Abstract][Full Text] [Related]
14. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. Fitzgerald JM; Ramchurren N; Rieger K; Levesque P; Silverman M; Libertino JA; Summerhayes IC J Natl Cancer Inst; 1995 Jan; 87(2):129-33. PubMed ID: 7707384 [TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Sibley K; Cuthbert-Heavens D; Knowles MA Oncogene; 2001 Feb; 20(6):686-91. PubMed ID: 11314002 [TBL] [Abstract][Full Text] [Related]